• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

    7/9/25 8:05:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LIXT alert in real time by email

    Article Indicates that Inhibition of PP2A Enhances Immunotherapy Response

    with LIXTE's Proprietary Compound LB100

    PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced that the medical journal Nature has published findings by a team of physician-scientists that validate LIXTE's ongoing clinical trials with its proprietary compound LB100 for Ovarian and Colorectal cancers (https://www.nature.com/articles/s41586-025-09203-8).

    A team led by principal investigator Amir Jazaeri, MD, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, studied survival outcomes of Ovarian Clear Cell Carcinoma (OCCC) patients treated with immune checkpoint blockade therapy (clinicaltrials.gov identifier: NCT03026062). The ;study showed that patients having tumors with inactivating mutations in PPP2R1A - the major scaffold subunit of protein phosphatase 2A (PP2A) - had significantly better overall survival, compared with patients who did not have this mutation in their tumors.

    Inactivating mutations in PPP2R1A are known to reduce the enzymatic activity of PP2A, which is the target of LIXTE's lead compound LB-100. Tumors with mutations in PPP2R1A were found to have increased the interferon gamma response pathway, which is known to be associated with improved immune checkpoint responses.

    LIXTE is currently investigating the activity of LB-100 in combination with checkpoint immunotherapy in two clinical trials. The first is enrolling patients with OCCC, led by Dr. Jazaeri at MD Anderson Cancer Center, and also is open at Northwester University. In this trial, LIXTE is collaborating with GSK to test LB-100 in combination with dostarlimab (anti PD1). In the second trial, at the Netherlands Cancer Institute, LIXTE is collaborating with Roche to test LB-100 in combination with atezolizumab (anti PDL1) in colon cancer patients.

    "Not only did we identify a new biomarker for improved survival with immunotherapy in ovarian cancer, but we also confirmed the correlation of this biomarker with survival benefit in other cancer types," said Dr. Jazaeri, who was co-senior author of the Nature article. "Since PPP2R1A mutations are relatively uncommon, we believe the same benefits may be possible by targeting the PPP2A pathway using drugs, which we currently are evaluating in a clinical trial at MD Anderson."

    Bas van der Baan, LIXTE's Chief Scientific Officer, added, "This work extends a body of pre-clinical evidence indicating that LB-100 is strongly synergistic with checkpoint immunotherapy in a range of cancer types. We look forward to the first results of our clinical studies in the second half of this year."

    About LIXTE Biotechnology Holdings, Inc.

    LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.

    LIXTE's lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about LIXTE can be found at www.lixte.com.

    Forward-Looking Statement Disclaimer

    This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company's ability to obtain and maintain compliance with Nasdaq's continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.

    The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.

    Readers are urged to read the risk factors set forth in the Company's filings with the United States Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information about LIXTE, Contact:

    For more information about LIXTE, Contact: [email protected]

    General Phone: (631) 830-7092; Investor Phone: (888) 289-5533

    or

    PondelWilkinson Inc. Investor Relations [email protected]

    Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962



    Primary Logo

    Get the next $LIXT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LIXT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LIXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO and Chairman of the Board Pursglove Geordan Garrett

      4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

      7/9/25 6:37:33 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Yen Yun

      4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

      7/9/25 11:52:58 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Brown Regina

      4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

      7/8/25 9:33:04 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIXT
    SEC Filings

    See more
    • SEC Form 8-K filed by Lixte Biotechnology Holdings Inc.

      8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

      7/11/25 8:45:10 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-1/A filed by Lixte Biotechnology Holdings Inc.

      S-1/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

      7/10/25 5:01:19 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

      7/8/25 5:29:11 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 67% to 25,000 units (SEC Form 4) (Amendment)

      4/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

      10/5/23 8:39:03 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Van Der Baan Bastiaan Jeroen bought $28,000 worth of shares (10,000 units at $2.80), increasing direct ownership by 1,000% to 11,000 units (SEC Form 4)

      4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

      10/5/23 8:36:30 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 33% to 20,000 units (SEC Form 4)

      4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

      10/4/23 6:10:01 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Lixte Biotechnology Holdings Inc.

      SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

      4/6/22 9:58:22 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Lixte Biotechnology Holdings Inc. (Amendment)

      SC 13G/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

      4/6/22 9:59:12 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed

      SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

      3/3/21 7:45:27 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIXT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

      New York, NY, July 09, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $1.5 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), in which it served as the exclusive placement agent. Lixte Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company focused on cancer drug development, completed the offering on July 8, 2025. The offering consisted of the sale of an aggregate of 974,026 shares of Common Stock (or Pre-Funded Warrants in lieu thereof). The public offering price per share of Common Stock was $1.54, and $1.53999 per Pre-Funded Warrant, which includes

      7/9/25 5:15:22 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

      Article Indicates that Inhibition of PP2A Enhances Immunotherapy Responsewith LIXTE's Proprietary Compound LB100 PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced that the medical journal Nature has published findings by a team of physician-scientists that validate LIXTE's ongoing clinical trials with its proprietary compound LB100 for Ovarian and Colorectal cancers (https://www.nature.com/articles/s41586-025-09203-8). A team led by principal investigator Amir Jazaeri, MD, professor of Gynecologic Oncology and Reproductive Medicine at The University of T

      7/9/25 8:05:00 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering

      PASADENA, CALIF, July 08, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) (the "Company"), a clinical stage pharmaceutical company, today announced the closing of a registered direct offering with accredited investors for the purchase and sale of approximately $1.5 million of shares of Common Stock (or Pre-Funded Warrants). The offering consisted of the sale of an aggregate of 974,026 shares of Common Stock (or Pre-funded Warrants in lieu thereof). The public offering price per share of Common Stock was $1.54 (or $1.53999 for each Pre-Funded Warrant, which is equal to the offering price per share of Common Stock sold in the offering minus an exercise price of $0.

      7/8/25 4:05:00 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIXT
    Leadership Updates

    Live Leadership Updates

    See more
    • LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

      PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Schellens brings to LIXTE more than 25 years of clinical experience as a medical oncologist, pharmacologist and clinical pharmacologist, including more than two decades developing and bringing new drugs to market. He assumes the CMO role at LIXTE effective August 1, 2024, succeeding James S. Miser, M.D., who is leaving the Company after serv

      6/3/24 8:30:00 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

      Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, announced that Bas van der Baan has been named as President and Chief Executive Officer of the Company, and as Vice Chairman of the Board of Directors, effective as of September 26, 2023. He has been a member of LIXTE'S Board of Directors since June 2022. Mr. van der Baan succeeds John S. Kovach, M.D., 87, who founded the Company in 2005 a

      9/26/23 8:30:00 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

      PASADENA, CA, June 21, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Bas van der Baan to its Board of Directors. He will serve as an independent director. Dr. John S. Kovach, Founder and Chief Executive Officer of Lixte, commented, "We are very pleased to welcome Mr. van der Baan to our Board of Directors. Mr. van der Baan has over 20 years of experience in the biotechnology industry with a key focus on oncology and diagnostics. He has extensive knowhow in the journey from clinical development to reimbursement and commercialization

      6/21/22 8:30:00 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care